Ruthsarian
Home
Sitemap
Q & A
Notice Board
PhEpi & PhV activities
Research Funding
Conferences & meetings
Recruitment
Links
Contact Us
Search Studies
The search criteria are non-mandatory. Therefore, not specifying any search criteria will return all database entries.
EU PAS Register Number:
EUPAS
Status of Study:
Planned
Ongoing
Finalised
Title of Study:
Acronym:
Study type:
Active surveillance
Observational study
Clinical trial
Other
Lead investigator:
Last Name
First Name
Study requested by a regulator:
Risk Management Plan:
Please select
Not applicable
EU RMP category 1 (imposed as condition of marketing authorisation)
EU RMP category 2 (specific obligation of marketing authorisation)
EU RMP category 3 (required)
Non-EU RMP only
Other registration numbers:
Country of regulator:
EMA
United States
Canada
Australia
Japan
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Switzerland
United Kingdom (Northern Ireland)
Other:
Coordinating Study entity:
AEMPS
AIBILI
AMSP
ANFOMED GmbH
ARS
ASSR Emilia-Romagna
AU-ADA
AXONAL-BIOSTATEM
Aarhus University Dept. of Clinical Epidemiology
Adelphi Real World
Aetion
Affective Disorders Research Group
ApHER
BCB Medical
BIPS GmbH
Biologic Studies Group
Bordeaux PharmacoEpi
Brighton Collaboration
CEDOC/FCM-UNL
CEFAR
CEIFE
CEMKA
CESME
CESP
CHI, University of Manchester
CHIP
CHRC
CIRFF-Unina
CMNS
CPRD
CRFV Sardegna
CRF_Campania
CRO
CRPV Lyon
CRPV-Bx
CSD MR France
Cancer Epidemiology Unit, University of Oxford
Capionis
Center for Research in Medical Pharmacology
Centre for Health Protection
Centre for Pharmacoepidemiology (CPE)
Centre of Clinical Pharmacology for Drug Evaluat
Centre of Biostatistics-UL
Cerner Enviza Clinical, Regulatory and Safety
Certara
ClinPharm, UnimiSacco
Clinical Pharmacology Department, HULP, UAM
Clinical Pharmacology Service HUPHM
Clinical Pharmacology Service, HUB/IDIBELL
Clinical Pharmacology at Karolinska
Clinical Trials Unit
CreativePhS
DAC
DAPI
DGRM-Infarmed
DIMDI
DRFZ
DSRU
Department for Pediatric Neurology
Department of Epidemiology Lazio Region, Italy
Department of Public Health Sciences
Dept. of Epi. Research
Dpt Pharmacoepedemiology
Drugs and Pregnancy
EORTC
EPIDEMIOLOGY- DSMB - UDINE UNIVERSITY
Embryotox Berlin
Epi-Consultant
EpiChron
EpiConcept
Eurotrials
Evidera
FICF
FPS
FV&JK Consulting
Fimea
Finnish Cancer registry
Florence PV and PE Research Unit
Friberg Research AB
GB PHARMA SERVICES & CONSULTING
GECEM
GISED
GPRI
Gerho
Gillian Hall
Grupo Asturiano de Farmacoepidemiología
HIPPOCRATES I.C.I.
HIRU
Haematology Oncology Leipzig
Hannover Medical School HTTG
Health Data Science
Health Search-SIMG
Hippocrates Research
Horiana
Hospital Clinic Barcelona
IADB.NL
IDIAPJGol
IKNL
IMIBE
IMS Health
IMSIE Cologne
INSPIRE srl
IPCRG
IPRI
IQVIA
IQVIA
IQVIA European Data Science Hub
IQVIA NL
IQVIA Real World Solutions
IRBLleida-UAC
IRFMN
ISP Navarra
Julius Clinical Research
KBC Zagreb
Kappa Santé
Kubadili
LA-SER Research
LSHTM
Labcorp
Laboratory of Hygiene and Environmental Protection
Logex
MAPI-ICON
MEMO
MFIR-Ulster
MUMC+
MedEngine
MediNeos
Medpace
NIPH
NPEU
Netherlands Pharmacovigilance Centre Lareb
Neurodevelopmental Pharmacovigilance Research
Numerus - Statistics and Pharmacoepidemiology
OPRI Pte Ltd
OXON
Optum
Outcome
P95
PAREXEL
PE2
PELyon
PEPSS
PHARMO Institute
PHE
PRC
PRC
PVZ FAKOS
PWA
Paris Pharmacoepidemiology Centre
Pasternak Pharmacoepidemiology Research Team
Patients Direct
Patras Center for Pharmacoepidemiological studies
PhV Regional Centre of Lombardy, Italy
PharmaSafe
Pharmacoepidemiology Research BfArM
Pharmacoepidemiology Research Group
Pharmacoepidemiology Unit - ISS
Pharmacol UNIVR
Pharmacovigilance Unit of Neurofarba Department
Pharmatelligence
Phase4CPH
Phisquare Institute
Phv Department -HALMED
PrimeVigilance/Ergomed
Psychepi Sweden
Quantify
Quintiles RWLPR
RCSI EMeRGe group
RTI-HS
Radboudumc
ReS
Rotterdam Study
SER
SLC e.V. - The Human Motion Institute
Sence
Spanish DILI Registry
Synapse Medicine
Syneos Health
TIS Helsinki
The University of Edinburgh
The Wolfson Centre for Personalised Medicine
UADRM
UBC
UCL School of Pharmacy
UFALBA
UFLVT
UFPorto
UFS
UL FFA
UMCU
UNIBO
UNIMIB
UOI
UPCET
UPO
Unit of Clinical Psychopharmacology - Verona
University of Bath
University of Helsinki, Public Health
University of Messina
University of Southern Denmark Pharmacoepi center
Uppsala Monitoring Centre
Utrecht University Pharmacoepidemiology Center
VACCINE.GRID
VHIR
Vaccine Safety Evaluation/THL
VarHa
WCT Evidence
WIT
Wolfson Unit, Newcastle
YOLARX Consultants
Yellow card Centre Scotland
ZEG Berlin
iBiMED
inVentiv Health Clinical
All
Other
Research Network:
ACRPV
AMSP
BIOBADASER
BIOREG
CARING
COVIDRIVE
DARWIN EU CC
DRIVE
E-CORE
ENTIS
EUDRAGENE
EULAR RODS
EURAS/ INAS
EUROCAT
EVICR.net
EuroDURG
European Forum for Primary Care
European TREAT Registry Taskforce
FP-MCRN
I-MOVE
IPDN
MEDICYS
MSDA
NEPI
Optimum Patient Care (OPC)
PGRx®
PRINTO
Psonet
RegiSCAR
ResearchLink
Respiratory Effectiveness Group (REG)
SIGMA
TEDDY
VAC4EU
redIAPP
All
Other
Country in which study is conducted:
Please select
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, The Democratic Republic of the
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Cyprus
Czechia
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Faeroe Islands
Falkland Islands (Malvinas)
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macau
North Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
São Tomé and Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Eswatini
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
Kosovo
Saint Barthelemy
Saint Martin (French Part)
Curaçao
South Sudan
United Kingdom (Northern Ireland)
Study drug
Substance Class (ATC Index):
e.g. C03 or diuretics
Substance (INN):
Brand Product Name:
Medical condition:
ENCePP Seal:
Yes
No
Population age:
Preterm newborns
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Other population:
Renal impaired
Hepatic impaired
Immunocompromised
Pregnant women
Scope of the Study:
Disease epidemiology
Risk assessment
Drug utilisation study
Effectiveness evaluation
Other
News
About Us
ENCePP Documents
Training in PhEpi and PV
Code of Conduct
Standards & Guidances
ENCePP Study Seal
Public Consultation
Glossary of terms
Resources Database
Partners forum
EU PAS Register
About EU PAS Register